Bajaj Healthcare seeks compulsory licence for Covid-19 drug Baricitinib

Eli Lilly has granted voluntary license to 6 Indian drugmakers for Baricitinib

Drugmaker Bajaj Healthcare (BHL) has requested the Indian patent office to grant a compulsory licence to make Baricitinib, an Eli Lilly drug which has shown promise in treating Covid-19.

Currently, Eli Lilly and company has received Emergency Use Authorization (EUA) from US Food and Drug Administration (FDA) for the distribution and emergency use of Baricitinib to be used in combination with remdesivir in hospitalised adult and pediatric patients aged more than two years with suspected or laboratory confirmed Covid-19 requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

EUA permits the emergency use of Baricitinib, in combination with